Related Experiment Video
Updated: Oct 29, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Aspirin withdrawal: A risk factor for ischemic stroke severity
H El Otmani1, M Berrada2, Z Abdulhakeem2
1Department of Neurology, Ibn Rochd Hospital, Hassan II University, Faculty of Medicine and Pharmacy, rue Tarik Ibn Ziad, 20360 Casablanca, Morocco; Laboratory of genetics and molecular pathology, Ibn Rochd Hospital, Hassan II University, Faculty of Medicine and Pharmacy, rue Tarik Ibn Ziad, 20360 Casablanca, Morocco.
Introduction:
Acetylsalicylic acid (ASA) cessation, is suggestive of a rebound phenomenon laying the ground for ischemic stroke (IS) re-occurrence but nothing is known about its implication for IS severity (ISS). Thus, the aim of our study is to examine whether or not aspirin withdrawal is a risk factor for ISS.
Patients And Methods:
This study, recruited patients having presented an IS in the following 2 weeks of ASA withdrawal, matched with treatment free cases. ISS was evaluated in all patients at admission using the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin scale (mRS) at 3 months' follow-up.
Findings:
Fifty cases were included in this study and fifty, manually matched, controls. ISS analysis found that the case group had a more severe stroke at admission (mean NIHSS: 12.76 (±7.319) in cases vs 10.04 (±5.562) in controls, P=0.039), with ASA discontinuation judged as a risk factor directly related to ISS regardless of the underlying cardiovascular risk factors (using the multivariate analysis).
Conclusion:
Our study's findings suggest that aspirin interruption over a 15-days period could result in a more severe IS in the acute phase. To our knowledge, no study has ever discussed this outcome, shedding the light on the pressing need for larger studies with various withdrawal periods to support these data.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Peripheral Artery Disease I: Introduction
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...

